Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) – Pipeline Review, H2 2016’, provides in depth analysis on Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted pipeline therapeutics.

The report provides comprehensive information on the Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83)

The report reviews Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics and enlists all their major and minor projects

The report assesses Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Astellas Pharma Inc.

Immunomic Therapeutics, Inc.

Vakzine Projekt Management GmbH

VBI Vaccines Inc

Vical Incorporated

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) Overview 7

Therapeutics Development 8

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Products under Development by Stage of Development 8

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Products under Development by Therapy Area 9

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Products under Development by Indication 10

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Products under Development by Companies 13

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Therapeutics Assessment 15

Assessment by Monotherapy/Combination Products 15

Assessment by Mechanism of Action 16

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Companies Involved in Therapeutics Development 21

Astellas Pharma Inc. 21

Immunomic Therapeutics, Inc. 22

Vakzine Projekt Management GmbH 23

VBI Vaccines Inc 24

Vical Incorporated 25

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Drug Profiles 26

Anti-IL-2R Monoclonal Antibody + LAMP-pp65 Dendritic Cell Vaccine - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

ASP-0113 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Cellular Immunotherpay to Target PP65 for Glioblastoma Multiforme - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

CyMVectin - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

PepVax - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Triplex - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

VBI-1901 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

VPM-2001 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Dormant Projects 40

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Discontinued Products 41

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Featured News & Press Releases 42

Oct 11, 2016: VBI Vaccines Completes Pre-IND Meeting for its Glioblastoma Immunotherapy Candidate 42

Oct 05, 2016: VBI Vaccines to Present at the World Vaccine Congress Europe 42

Sep 20, 2016: Vical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus Vaccine (ASP0113) in Kidney Transplant Patients 43

Aug 29, 2016: VBI Vaccines to Present at the Immuno-Oncology Summit 43

Jun 16, 2016: VBI Vaccines Announces Medulloblastoma Immunotherapy Program 44

Mar 29, 2016: VBI To Present At The World Vaccine Congress Washington 45

Mar 07, 2016: VBI Vaccines Presents New Data Supporting its Glioblastoma Immunotherapy Program at the Keystone Symposia Cancer Vaccines Conference 46

Nov 20, 2015: VBI Vaccines Presents Update and New Data Supporting its Glioblastoma Immunotherapy Program at the ESMO Symposium on Immuno-Oncology 47

Nov 06, 2015: VBI Vaccines to Present Update and New Data Supporting its CMV Vaccine Program at the World Vaccine Congress Europe 48

May 21, 2015: Vical Announces Completion of Enrollment in Phase 2 Clinical Trial of Investigational CMV Vaccine in Kidney Transplant Recipients 49

Apr 21, 2015: Vical Announces Presentation of Preclinical Data for Congenital CMV DNA Vaccine at International Conference 50

Dec 10, 2013: Astellas and Vical Announce Initiation of Phase 2 Trial of ASP0113, a Cytomegalovirus Vaccine, in Solid Organ Transplant Recipients 50

Jun 25, 2013: Vical And Astellas Initiate Phase III Trial Of ASP0113 Cytomegalovirus Vaccine 51

Apr 02, 2012: Astellas And Vical Advance Toward Phase III Trial Of TransVax CMV Vaccine Triggering $10m Milestone Payment To Vical 51

Jan 11, 2012: Vical Provides Update On CyMVectin Prophylactic Vaccine 52

Appendix 53

Methodology 53

Coverage 53

Secondary Research 53

Primary Research 53

Expert Panel Validation 53

Contact Us 53

Disclaimer 54

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Stage and Mechanism of Action, H2 2016 16

Number of Products by Stage and Route of Administration, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 20

Pipeline by Astellas Pharma Inc., H2 2016 21

Pipeline by Immunomic Therapeutics, Inc., H2 2016 22

Pipeline by Vakzine Projekt Management GmbH, H2 2016 23

Pipeline by VBI Vaccines Inc, H2 2016 24

Pipeline by Vical Incorporated, H2 2016 25

Dormant Projects, H2 2016 40

Discontinued Products, H2 2016 41

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Routes of Administration, H2 2016 17

Number of Products by Stage and Routes of Administration, H2 2016 17

Number of Products by Molecule Types, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 19

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports